AIFA. Pharmaceutical expenditure monitoring January-October 2022

Aifa has published the January-October 2022 data relating to NHS pharmaceutical expenditure

The Italian Medicines Agency (Aifa) has published the «Monitoring of national and regional pharmaceutical expenditure» referring to the period January-October 2022. Pharmaceutical expenditure, calculated net of discounts, of the total co-participation and pay-back paid to the Regions by pharmaceutical companies is 6,341.3 million euros.

This highlights a slight increase, compared to the previous year, of +69.2 million euros, "returning to 2020 levels". The number of prescriptions disbursed (465.2 million) showed the same trend with respect to this increase, which shows a change of +2.0% on 2021. The incidence of the ticket, i.e. the "out of pocket" expense of patients, increased by +1.4%. As for drug consumption, the number of daily doses shows an increase of +0.2%, equal to an increase of 39.7 million dispensed.

Regional trend of approved pharmaceuticals

With reference to the regional approved pharmaceutical expenditure incurred through the payment of the summary accounting slip to private and public territorial pharmacies, the Aifa report shows that the Regions with the greatest percentage increase are Lombardy (+4.4%), PA Trento (+3, 9%) and Molise (+3.5%).

The Region with the greatest decline is Umbria (-4.6%). In most of the Regions there is an increasing trend of the concessions, with a recovery compared to the negative trend highlighted in the previous year. Other regions with a positive gap include Abruzzo and Emilia-Romagna (+2.6%), Sardinia (+2.2%) and Tuscany (+2.0%). Valle d'Aosta and Liguria (+0.1%), Calabria (+0.2%) and Puglia (+0.4%) show a slight increase.

 

Exit mobile version